| Autor: |
Serrano López J; Experimental Hematology Lab, IIS-Fundación Jimenez Díaz, UAM, Madrid, Spain., Jiménez-Jiménez C; Department of Chemistry in Pharmaceutical Sciences, School of Pharmacy, Universidad Complutense de Madrid, UCM, Instituto Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain.; CIBER-BBN, Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, Madrid, Spain., Chutipongtanate S; Departments of Pediatrics, Clinical Epidemiology and Biostatistics, Chakri Naruebodindra Medical Institute, Bangkok, Thailand.; Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand., Serrano J; Hematology Department, Reina Sofía University Hospital/Maimonides Biomedical Research Institute of Córdoba (IMIBIC)/University of Córdoba, Spain., Rodríguez-Moreno M; Pathology, Fundación Jimenez Díaz, Madrid, Spain., Jiménez Á; Genomics Unit, IMIBIC (Maimonides Biomedicas Research Institute of Cordoba), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain., Jiménez Y; Immunology Department, IIS Fundación Jimenez Díaz, UAM, Madrid, Spain., G Pedrero S; Experimental Hematology Lab, IIS-Fundación Jimenez Díaz, UAM, Madrid, Spain., Laínez D; Experimental Hematology Lab, IIS-Fundación Jimenez Díaz, UAM, Madrid, Spain., Alonso-Domínguez JM; Experimental Hematology Lab, IIS-Fundación Jimenez Díaz, UAM, Madrid, Spain.; Hematology, Hospital Universitario Fundación Jimenez Díaz, Madrid, Spain., Llamas Sillero P; Experimental Hematology Lab, IIS-Fundación Jimenez Díaz, UAM, Madrid, Spain.; Hematology, Hospital Universitario Fundación Jimenez Díaz, Madrid, Spain., Piris MÁ; Pathology, Fundación Jimenez Díaz, Madrid, Spain., Sánchez-García J; Hematology Department, Reina Sofía University Hospital/Maimonides Biomedical Research Institute of Córdoba (IMIBIC)/University of Córdoba, Spain. |
| Abstrakt: |
Activated B-cell (ABC) lymphoma, a distinct molecular entity within diffuse large B-cell lymphoma (DLBCL), remains highly incurable, showing a worse response to standard immunochemotherapy. The discouraging results obtained in several clinical trials using proteasome inhibitors, tyrosine kinase inhibitors, or immunomodulators, lead to an intense search for new, potentially druggable biomarkers in DLBCL. In this study, we designed an experimental strategy for DLBCL to discover high- and low-abundance RNA-seq-derived transcripts involved in the oncogenic phenotype in patients diagnosed with ABC-DLBCL. Based on the results of a comparative analysis, 79 DE genes and two enriched gene sets related to metabolism and immunity were selected. Genes related to drug resistance, anti-inflammatory response, and tumor-cell dissemination were found to be up-regulated, while tumor suppressor genes were down-regulated. Then, we searched for the perturbagens most suitable for gene expression profiling (GEP) by iLINCS-CMap. Herein, we present a novel experimental approach that connects the omics signature of DLBCL with potential drugs for more accurate treatments. |
